Equity Analysis /

Biotech Stocks: High Idiosyncratic Risks, High Alpha?

    31 May 2022
    Published byFactorResearch
    1. Biotechnology companies have the potential to change our lives dramatically
    2. However, the performance of biotech stocks has been unimpressive since 1993
    3. Fund managers have failed to generate alpha in the sector